公司资料
4D Molecular Therapeutics, Inc. 股价、新闻与催化剂
- 股票代码:
- FDMT
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
13.84 USD (-3.28%)
收盘价
最后更新: 2026年10月1日
485M USD
市值
股价为何变动
最新监测到的公司动态为“4DMT to Host Investor Day on October 21, 2026”。相应的收盘价反应尚未产生。
公司概览
Genetic Medicines Company
4D Molecular Therapeutics develops genetic medicines using an engineered AAV vector platform known as Therapeutic Vector Evolution. The technology is designed to select vectors for specific tissues and routes of administration rather than relying only on naturally occurring viral capsids.
4D-150 Retinal Franchise
4D-150 is an intravitreal dual-transgene therapy that expresses both aflibercept and an anti-VEGF-C molecule. It is being developed for wet age-related macular degeneration and diabetic macular edema with the goal of providing durable control after a single administration.
Late-Stage Ophthalmology Development
The 4FRONT pivotal program evaluates 4D-150 in wet age-related macular degeneration, while a separate Phase 3 strategy is advancing in diabetic macular edema. These studies position ophthalmology as the company's principal near-term value driver.
Broader Retinal Pipeline
4D-175 is being developed for geographic atrophy and extends the platform beyond VEGF-driven retinal disease. The program reflects the company's ability to design vectors and payloads for additional degenerative eye conditions.
Aerosol Gene Therapy for Cystic Fibrosis
4D-710 is an inhaled gene therapy intended to deliver a functional CFTR transgene to airway cells. The program targets people with cystic fibrosis who may not benefit adequately from existing CFTR modulators.
未来催化剂
- Initiation of a Phase 3 study of 4D-150 in diabetic macular edema in the third quarter of 2026.
- Two-year SPECTRA data for 4D-150 in diabetic macular edema in the fourth quarter of 2026.
- Updated AEROW clinical data for 4D-710 in cystic fibrosis in the fourth quarter of 2026.
- Topline results from the 4FRONT-1 pivotal study of 4D-150 in the second quarter of 2027.
- Topline results from the 4FRONT-2 pivotal study of 4D-150 in the second half of 2027.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。